MIT Receives $10.4 Million BioManufacturing Grant - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

MIT Receives $10.4 Million BioManufacturing Grant


The Biomanufacturing Research Program (BioMAN) at Massachusetts Institute of Technology (MIT) has received $10.4 Million from the Defense Advanced Research Projects Agency (DARPA) to develop new technologies and manufacturing platforms that will provide an emergency supply of medicines for front-line military medics. This project is part of DARPA’s Biologically-derived Medicines on Demand (BioMOD) program, which aims to manufacture biologic drugs on demand in a forward operations setting where resources are often limited and make these drugs available in 24 hours.

MIT will be responsible for developing innovative methodologies for engineering robust, flexible microbial strains capable of synthesizing multiple protein-based therapeutics, as well as portable device platforms for rapid manufacturing of multiple biologics with high purity, efficacy and potency at the point-of-care.

“To make and release such medications on fast timescales will require orders of magnitude improvements on today’s manufacturing practices,” commented J. Christopher Love, lead investigator and associate professor of Chemical Engineering at MIT, in a press statement. “The goal for BioMAN is to transform biologic drug manufacturing from a time-consuming, step-wise process to a tightly integrated one for small-scale production.” The implications are tremendous, according to Love. “Imagine how having rapid access to drugs in remote settings could change lives or how such new capabilities might promote better global access to these costly drugs through distributed production.”

BioMAN, part of MIT’s Center for Biomedical Innovation (CBI), seeks to develop new knowledge, science, technologies, and strategies that advance the manufacture and global delivery of high quality biopharmaceuticals. “In BioMAN, we have created a unique ecosystem, where MIT and other affiliated faculty work closely with the biomanufacturing industry, as well as government and regulatory communities, to examine key issues in biomanufacturing and see new manufacturing innovations implemented,” said BioMAN’s program director, Stacy Springs.

Source: MIT

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here